Anti-il-2 antibody combinations and methods of use thereof

A method of treating an unresectable locally advanced or metastatic solid cancer in a subject, said method comprising administering to said subject multiple doses of an anti-IL-2 antibody or a pharmaceutical composition thereof, a loading dose of IL-2 or a pharmaceutical composition thereof, and at least one booster dose of IL-2 or a pharmaceutical composition thereof, said IL-2 antibody comprising a heavy chain variable region (VH) comprising heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3 and a light chain variable region (VL) comprising light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3,

• wherein said HCDR1 comprises the amino acid sequence of SEQ ID NO:1, said HCDR2 comprises the amino acid sequence of SEQ ID NO:2, said HCDR3 comprises the amino acid sequence of SEQ ID NO:3, said LCDR1 comprises the amino acid sequence of SEQ ID NO:4, said LCDR2 comprises the amino acid sequence of DAS, and said LCDR3 comprises the amino acid sequence of SEQ ID NO:5;
• wherein said loading dose and booster dose of IL-2 are subcutaneously administered at a dose of between about 15,000 IU/kg of said subject's body weight and 500,000 IU/kg of said subject's body weight;
• wherein said pharmaceutical composition(s) further comprises a pharmaceutically acceptable carrier,
• thereby treating said unresectable locally advanced or metastatic solid cancer in said subject.